Literature DB >> 17470524

Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.

Theunis C Goosen1, Jonathan N Bauman, John A Davis, Chongwoo Yu, Susan I Hurst, J Andrew Williams, Cho-Ming Loi.   

Abstract

Gemfibrozil coadministration generally results in plasma statin area under the curve (AUC) increases, ranging from moderate (2- to 3-fold) with simvastatin, lovastatin, and pravastatin to most significant with cerivastatin (5.6-fold). Inhibition of statin glucuronidation has been postulated as a potential mechanism of interaction (Drug Metab Dispos 30:1280-1287, 2002). This study was conducted to determine the in vitro inhibitory potential of fibrates toward atorvastatin glucuronidation. [(3)H]Atorvastatin, atorvastatin, and atorvastatin lactone were incubated with human liver microsomes or human recombinant UDP-glucuronosyltransferases (UGTs) and characterized using liquid chromatography (LC)/tandem mass spectrometry and LC/UV/beta-radioactivity monitor/mass spectrometry. [(3)H]Atorvastatin yields a minor ether glucuronide (G1) and a major acyl glucuronide (G2) with subsequent pH-dependent lactonization of G2 to yield atorvastatin lactone. Atorvastatin lactonization best fit substrate inhibition kinetics (K(m) = 12 microM, V(max) = 74 pmol/min/mg, K(i) = 75 microM). Atorvastatin lactone yields a single ether glucuronide (G3). G3 formation best fit Michaelis-Menten kinetics (K(m) = 2.6 microM, V(max) = 10.6 pmol/min/mg). Six UGT enzymes contribute to atorvastatin glucuronidation with G2 and G3 formation catalyzed by UGTs 1A1, 1A3, 1A4, 1A8, and 2B7, whereas G1 formation was catalyzed by UGTs 1A3, 1A4, and 1A9. Gemfibrozil, fenofibrate, and fenofibric acid inhibited atorvastatin lactonization with IC(50) values of 346, 320, and 291 microM, respectively. Based on unbound fibrate concentrations at the inlet to the liver, these data predict a small increase in atorvastatin AUC (approximately 1.2-fold) after gemfibrozil coadministration and no interaction with fenofibrate. This result is consistent with recent clinical reports indicating minimal atorvastatin AUC increases ( approximately 1.2- to 1.4-fold) with gemfibrozil.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17470524     DOI: 10.1124/dmd.107.015230

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  19 in total

1.  Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.

Authors:  Miroslav Dostalek; Wai-Johnn Sam; Komal R Paryani; Joyce S Macwan; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

Review 2.  Mechanisms and assessment of statin-related muscular adverse effects.

Authors:  Dirk Moßhammer; Elke Schaeffeler; Matthias Schwab; Klaus Mörike
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

3.  Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?

Authors:  Gualberto Ruaño; Paul D Thompson; John P Kane; Clive R Pullinger; Andreas Windemuth; Richard L Seip; Mohan Kocherla; Theodore R Holford; Alan H B Wu
Journal:  Pharmacogenomics       Date:  2010-07       Impact factor: 2.533

4.  Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.

Authors:  Alice C Rodrigues; Elida Adalgisa Neri; Sidney Veríssimo-Filho; Nancy Amaral Rebouças; Rosario D C Hirata; Ai-Ming Yu
Journal:  Eur J Pharm Sci       Date:  2016-08-26       Impact factor: 4.384

5.  Characterization of Statin-Associated Myopathy Case Reports in Thailand Using the Health Product Vigilance Center Database.

Authors:  Pornwalai Boonmuang; Surakit Nathisuwan; Nathorn Chaiyakunapruk; Wimon Suwankesawong; Pattreya Pokhagul; Nattawat Teerawattanapong; Pairin Supsongserm
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

Review 6.  How do you treat patients with myalgia who take statins?

Authors:  Saadi A Siddiqi; Paul D Thompson
Journal:  Curr Atheroscler Rep       Date:  2009-01       Impact factor: 5.113

Review 7.  Myopathy with statin-fibrate combination therapy: clinical considerations.

Authors:  Terry A Jacobson
Journal:  Nat Rev Endocrinol       Date:  2009-07-28       Impact factor: 43.330

8.  Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.

Authors:  A S Darwich; D Pade; K Rowland-Yeo; M Jamei; A Asberg; H Christensen; D M Ashcroft; A Rostami-Hodjegan
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-12

Review 9.  Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

Authors:  Elisavet Moutzouri; Anastazia Kei; Moses S Elisaf; Haralampos J Milionis
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 10.  Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.

Authors:  Nada Božina; Lana Ganoci; Livija Simičević; Katarina Gvozdanović; Iva Klarica Domjanović; Margareta Fistrek Prlić; Tena Križ; Ana Borić Bilušić; Mario Laganović; Tamara Božina
Journal:  Arh Hig Rada Toksikol       Date:  2021-06-28       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.